MedTrace Logo

A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers

NCT01107054 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2011-01-13

No results posted yet for this study

Summary

A study to determine the cardiovascular effects of PF00610335 in healthy volunteers.

Conditions

Interventions

DRUG

PF-00610355

An orally inhaled dose of PF-00610355 450 µg on days 1 to 4

DRUG

PF-00610355

An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4

DRUG

moxifloxacin

A single oral dose of moxifloxacin 400 mg on Day 4.

DRUG

placebo

A single oral dose of non-matched placebo on Day 4.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2010-09-30
Completion
2010-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01107054 on ClinicalTrials.gov